As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

US stocks closed lower afer the S&P 500 touched an intraday record high early in the day. As tariff worries eased, mixed ...

Novo Nordisk shares surged on the results of a new obesity-drug study Friday. The Danish pharmaceutical giant behind Ozempic ...

And the Fed isn't alone in its concerns about inflation. Today's University of Michigan consumer sentiment data showed ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.BqoHa0WQ.js ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

The S&P 500 closed lower after hitting new records on Friday, as investors took some profit to end a solid week centered on President Donald Trump 's return to the White House.

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...